Skip to main content

Dr. James Harding, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
19
In the NPI registry since
2008
Medicare patients seen, 2024
175

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Medical school: Albert Einstein College of Medicine of Yeshiva University
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    NY license 250863

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
175
Services billed
803
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes664144
New patient office or other outpatient visit, 60-74 minutes5050
Established patient office or other outpatient visit, 20-29 minutes2521

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 21 payments worth $35,148 in total to this clinician.

By company
Jazz Pharmaceuticals Inc.$19,751
AstraZeneca Pharmaceuticals LP$5,470
AbbVie Inc.$3,820
Eisai Inc.$2,400
E.r. Squibb & Sons, L.l.c.$1,920
Merck Sharp & Dohme LLC$1,678
AstraZeneca Ab$60.00
Servier Bioinnovation$50.00
By type
Consulting Fee$25,739
Travel and Lodging$7,941
Compensation for services other than consulting (speaking, faculty)$1,208
Food and Beverage$260

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$9,476
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind
$6,252
Sep 11, 2025AstraZeneca Pharmaceuticals LP
Sep 11, 2025
Consulting Fee$4,100
Jun 5, 2025AbbVie Inc.
Jun 5, 2025
Consulting Fee$3,625
Jul 2, 2025Eisai Inc.
Jul 2, 2025
Consulting Fee
Lenvima · Oncology
$2,400
Dec 8, 2025E.r. Squibb & Sons, L.l.c.
Dec 8, 2025
Consulting Fee$1,920
Jun 25, 2025AstraZeneca Pharmaceuticals LP
Jun 25, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$1,370
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$1,208
Jun 16, 2025Jazz Pharmaceuticals Inc.
Jun 16, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$1,170
Jan 20, 2025Merck Sharp & Dohme LLC
Jan 20, 2025
Consulting Fee
ENDOCRINOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$763
All 17 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 8, 2025E.r. Squibb & Sons, L.l.c.
Dec 8, 2025
Consulting Fee$1,920
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$9,476
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind
$6,252
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$1,208
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind
$541
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to New York, NY · in-kind
$180
Nov 3, 2025Jazz Pharmaceuticals Inc.
Nov 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to New York, NY · in-kind
$180
Oct 8, 2025Merck Sharp & Dohme LLC
Oct 8, 2025
Consulting Fee
ENDOCRINOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$610
Sep 11, 2025AstraZeneca Pharmaceuticals LP
Sep 11, 2025
Consulting Fee$4,100
Sep 10, 2025Merck Sharp & Dohme LLC
Sep 10, 2025
Consulting Fee
ENDOCRINOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$305
Jul 2, 2025Eisai Inc.
Jul 2, 2025
Consulting Fee
Lenvima · Oncology
$2,400
Jun 25, 2025AstraZeneca Pharmaceuticals LP
Jun 25, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$1,370
Jun 16, 2025Jazz Pharmaceuticals Inc.
Jun 16, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$1,170
Jun 5, 2025AbbVie Inc.
Jun 5, 2025
Consulting Fee$3,625
Jun 5, 2025AbbVie Inc.
Jun 5, 2025
Travel and Lodging
travel to CHICAGO, IL · in-kind
$44.56
Jan 20, 2025Merck Sharp & Dohme LLC
Jan 20, 2025
Consulting Fee
ENDOCRINOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$763
Jan 11, 2025Jazz Pharmaceuticals Inc.
Jan 11, 2025
Travel and Lodging
travel to Berlin, Germany · in-kind
$743

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $1,113,893 in research payments for these studies, mostly to the institutions running them.

  • A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer wit…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.
    Jazz Pharmaceuticals Inc.
  • Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
    AbbVie Inc. · Recruiting · NCT06084481
  • Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 (Brigimadlin) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarc…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
    AbbVie Inc.
  • A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
    Jazz Pharmaceuticals Inc.
  • A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
    E.r. Squibb & Sons, L.l.c.
  • Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 (Brigimadlin) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarc…
    Boehringer Ingelheim Pharma GmbH & Co.kg

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1306003793. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.